Klingemann H G, Kosukavak M, Höfeler H, Havemann K
Hoppe Seylers Z Physiol Chem. 1983 Mar;364(3):269-77. doi: 10.1515/bchm2.1983.364.1.269.
The glycoprotein fibronectin is, as well as by various other cells, also produced in leucocytes and is said to play an important role in malignant transformation of cells. Therefore, the behaviour of plasma fibronectin and of factor VIII R:AG was investigated in acute leukaemia in order to prove their significance as prognostic and therapeutic markers (method: electroimmunoassay). In patients with acute myeloid leukaemia (n = 29) and acute lymphoblastic leukaemia (n = 11) no significant changes in fibronectin concentration could be evaluated. Fibronectin levels declined significantly only during therapy with asparaginase in patients with acute lymphoblastic leukaemia, probably as a result of disturbed synthesis in the liver. Using crossed immunoelectrophoresis against fibronectin antiserum, one normal and one slower migrating antigen (FN:C) could be observed in nearly all plasma samples in patients with acute leukaemia. By means of in vitro tests with highly purified substances and intermediate gel electrophoresis it could be shown that FN:C represents fibronectin which has bound fibrinogen, probably crosslinked by activated factor XIII. Factor VIII R:AG was found to be greatly raised in patients with acute leukaemia--up to 1400% of the normal level. Increased levels correlated well with a worsening of the disease. The protein seems to be suitable for estimating the activity and prognosis of acute leukaemia.
糖蛋白纤连蛋白不仅由多种其他细胞产生,白细胞也能产生,据说它在细胞的恶性转化中起重要作用。因此,为了证明血浆纤连蛋白和因子VIII R:AG作为预后和治疗标志物的意义,对急性白血病患者的血浆纤连蛋白和因子VIII R:AG的行为进行了研究(方法:免疫电泳法)。在急性髓细胞白血病患者(n = 29)和急性淋巴细胞白血病患者(n = 11)中,未评估出纤连蛋白浓度有显著变化。仅在急性淋巴细胞白血病患者接受天冬酰胺酶治疗期间,纤连蛋白水平显著下降,这可能是肝脏合成紊乱的结果。用抗纤连蛋白抗血清进行交叉免疫电泳,在急性白血病患者的几乎所有血浆样本中可观察到一种正常的和一种迁移较慢的抗原(FN:C)。通过用高纯度物质进行体外试验和中间凝胶电泳表明,FN:C代表已结合纤维蛋白原的纤连蛋白,可能由活化的因子XIII交联。发现急性白血病患者的因子VIII R:AG大幅升高——高达正常水平的1400%。水平升高与疾病恶化密切相关。该蛋白似乎适用于评估急性白血病的活性和预后。